A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804
Overview
- Phase
- Phase 1
- Intervention
- PF-00299804
- Conditions
- Oral Cavity Cancer
- Sponsor
- University Health Network, Toronto
- Enrollment
- 13
- Locations
- 1
- Primary Endpoint
- To assess the degree of modulation of the proliferation index, ki-67, in the primary tumor of OCC specimens following a short, preoperative course of PF-00299804
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.
Detailed Description
This is a single-center, randomized, double-blinded, biomarker driven, preoperative window of opportunity study with a pharmacodynamic primary endpoint. Patients with resectable, histologically confirmed OCC for whom surgical treatment is planned as definitive management, will be randomized 2:1 to receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days or to Matching Placebo for 7-11 days depending on surgery schedule. The target is a total of 8 days of treatment but with a minimum of 7 and a maximum of 11 dosing days. All patients will receive surgery as per standard of care without delay. Biomarkers from the surgical specimen and baseline tumor biopsy or consent to provide a tumor block from existing primary diagnostic tumor biopsy completed within 90 days will be evaluated for primary and secondary pharmacodynamic endpoints.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed, voluntary informed consent provided
- •Willing and able to comply with scheduled visits, treatment plan, tests, other study procedures
- •Patient must be diagnosed with histologically confirmed oral cavity squamous cell carcinoma (OCC) (lip, floor of mouth, anterior 2/3 tongue, buccal mucosa, upper and lower gingiva, hard palate and retromolar trigone) considered resectable (T1-4a, N0-2, M0; (without distant metastases)) for whom surgical resection of tumor is planned. Patients with distant metastatic disease or diagnosis of SCCHN may not be enrolled
- •Must be able to provide a fresh tumor biopsy prior to randomization for histopathological and biomarker evaluation. No anti-neoplastic treatment allowed between obtaining baseline tumor specimen and randomization. Patients who decline an in-house fresh pre-treatment tumor biopsy must give consent to provide a tumor block from an existing diagnostic primary tumor biopsy completed within 90 days of enrolment
- •Prior treatment with agents targeted to epidermal growth factor receptor is not allowed.
- •No prior chemotherapy or radiotherapy (to primary site/nodes).
- •Patient must not have received prior anti-neoplastic treatment within past 2 years
- •Any treatment-related acute toxicity, including laboratory abnormalities, must have recovered to CTCAE Grade 1 (v.4.0) or baseline, except toxicity not considered a safety risk.
- •ECOG performance status of 0-
- •Patient must have adequate organ function as determined by the following criteria:
Exclusion Criteria
- •Patients who require segmental mandibulectomy for surgical resection of oral cavity tumor will not be enrolled
- •Primary site of head and neck carcinoma in nasopharynx, skin, or unknown
- •Prior or concurrent radiation therapy to tumor at site of planned resection
- •Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of PF-00299804
- •Requirement for treatment with drugs that are highly dependent on CYP2D6 for metabolism since PF-00299804 is a potent CYP2D6 inhibitor in in vitro assays
- •Patients currently taking drugs that have a risk of causing Torsades de Pointes
- •Any acute or chronic medical, psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry in the trial
- •Other serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment as determined by investigator
- •Dementia or significantly altered mental status that would limit the ability to obtain informed consent and compliance with the requirements of this protocol
- •Patients breastfeeding or pregnant are excluded. All female patients with reproductive potential must have a negative pregnancy test within 72 hours prior to treatment.
Arms & Interventions
PF-00299804
Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
Intervention: PF-00299804
Placebo arm
Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
Intervention: PF-00299804
Outcomes
Primary Outcomes
To assess the degree of modulation of the proliferation index, ki-67, in the primary tumor of OCC specimens following a short, preoperative course of PF-00299804
Time Frame: 8-11 months
Secondary Outcomes
- To evaluate changes in tissue and blood-based biomarkers before, during and after treatment with PF-00299804 and attempt to correlate with gene expression changes, EGFR variant III mutation status, EGFR amplification and histopathological changes(8-11 months)
- To assess the relationship between pharmacokinetic parameters and molecular changes detected in OCC tumor specimens(8-11 months)
- To assess the safety and tolerability of pre-operative PF-00299804(8-11 months)
- To quantitatively assess the effect of PF-00299804 on tumorigenic cells expressing CD44+/Lin- markers in paired OCC tumor specimens(8-11 months)
- To evaluate gene expression changes in tumor tissue before and after treatment with PF00299804(8-11 months)